IGC Pharma
5 hedge funds and large institutions have $36K invested in IGC Pharma in 2014 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, reducing their positions, and 3 closing their positions.
3.06% less ownership
Funds ownership: 3.47% → 0.41% (-3.1%)
17% less funds holding
Funds holding: 6 → 5 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
93% less capital inflows, than outflows
Capital inflows: $29.6K | Capital outflows: $432K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Virtu KCG Holdings
New York
|
+$19.5K |
| 2 |
Creative Planning
Overland Park,
Kansas
|
+$8.03K |
| 3 |
UBS
Zurich,
Switzerland
|
+$2.06K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
-$417K |
| 2 |
Goldman Sachs
New York
|
-$15K |
| 3 |
B. Riley Wealth Advisors
Boca Raton,
Florida
|
-$320 |
IGC Hedge Fund Activity: Q3 2014 in Review
5 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in IGC Pharma (IGC) for Q3 2014, worth a combined $36K — down 92% from $462K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of IGC and 2 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.
The largest buyer was Virtu KCG Holdings, opening a new position worth an estimated $19.5K. The largest seller was Wells Fargo, exiting entirely with an estimated $417K sold.
- 5 institutional investors held IGC Pharma (IGC) as of Q3 2014, down from 6 in Q2 2014.
- Funds reported $36K of IGC Pharma stock for Q3 2014, down 92% quarter-over-quarter.
- 2 funds opened new IGC Pharma positions in Q3 2014 and 3 closed out, a net change of -1 holder.
- The largest IGC Pharma buyer in Q3 2014 was Virtu KCG Holdings, an estimated $19.5K added.
- The largest IGC Pharma seller in Q3 2014 was Wells Fargo, an estimated $417K sold.
Based on aggregated 13F filings for Q3 2014.